Tamiko Nishimura
Overview
Explore the profile of Tamiko Nishimura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Page P, Dastous S, Richard P, Pavic M, Nishimura T, Riazalhosseini Y, et al.
Cancer Cell Int
. 2025 Feb;
25(1):71.
PMID: 40016765
Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is one of the first truncal events in clear cell Renal Cell Carcinoma (ccRCC) tumorigenesis. The accumulation of Hypoxia Induced Factor...
2.
Attias M, Alvarez F, Al-Aubodah T, Istomine R, McCallum P, Huang F, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39762077
Background: Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) are the first line of treatment for many solid tumors including melanoma. PD-1 blockade enhances the effector functions of melanoma-infiltrating...
3.
Spinelli C, Adnani L, Meehan B, Montermini L, Huang S, Kim M, et al.
Nat Commun
. 2024 Apr;
15(1):2865.
PMID: 38570528
Targeting neovascularization in glioblastoma (GBM) is hampered by poor understanding of the underlying mechanisms and unclear linkages to tumour molecular landscapes. Here we report that different molecular subtypes of human...
4.
Demko N, Glennon K, Arseneault M, Lach K, Nishimura T, Tanguay S, et al.
Int J Surg Pathol
. 2022 Dec;
31(5):890-895.
PMID: 36562104
Clear cell papillary renal cell tumor (CCPRCT) is a distinct clinical entity with characteristic pathological features and non-aggressive clinical behavior. Diagnostically challenging cases present when there are immunomorphological findings of...
5.
Perron G, Jandaghi P, Moslemi E, Nishimura T, Rajaee M, Alkallas R, et al.
Commun Biol
. 2022 Aug;
5(1):851.
PMID: 35987939
Measuring mRNA decay in tumours is a prohibitive challenge, limiting our ability to map the post-transcriptional programs of cancer. Here, using a statistical framework to decouple transcriptional and post-transcriptional effects...
6.
Nishimura T, Fakim H, Brandmann T, Youn J, Gingras A, Jinek M, et al.
Nucleic Acids Res
. 2018 Oct;
46(22):12008-12021.
PMID: 30364987
Meiosis arrest female 1 (MARF1) is a cytoplasmic RNA binding protein that is essential for meiotic progression of mouse oocytes, in part by limiting retrotransposon expression. MARF1 is also expressed...
7.
8.
Nishimura T, Padamsi Z, Fakim H, Milette S, Dunham W, Gingras A, et al.
Cell Rep
. 2015 Jun;
11(9):1425-36.
PMID: 26027925
Eukaryotic mRNA degradation often initiates with the recruitment of the CCR4-NOT deadenylase complex and decay factors to the mRNA 3' terminus. How the 3'-proximal decay machinery interacts with the 5'-terminal...
9.
Hinttala R, Sasarman F, Nishimura T, Antonicka H, Brunel-Guitton C, Schwartzentruber J, et al.
Hum Mol Genet
. 2015 Apr;
24(14):4103-13.
PMID: 25911677
Protein synthesis in mitochondria is initiated by formylmethionyl-tRNA(Met) (fMet-tRNA(Met)), which requires the activity of the enzyme MTFMT to formylate the methionyl group. We investigated the molecular consequences of mutations in...
10.
Sasarman F, Nishimura T, Antonicka H, Weraarpachai W, Shoubridge E
Hum Mol Genet
. 2014 Sep;
24(2):480-91.
PMID: 25214534
French Canadian Leigh Syndrome (LSFC) is an early-onset, progressive neurodegenerative disorder with a distinct pattern of tissue involvement. Most cases are caused by a founder missense mutation in LRPPRC. LRPPRC...